Treatment of painful diabetic neuropathy

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 1, 2015, Pages 15-28

  Javed, Saad ^a   Petropoulos, Ioannis N ^a   Alam, Uazman ^b   Malik, Rayaz A ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Diabetes mellitus; Management; Neuropathy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; BENFOTIAMINE; C PEPTIDE; CAPSAICIN; CARBAMAZEPINE; DELAPRIL; DESIPRAMINE; DULOXETINE; FENOFIBRATE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; MANIDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; THIOCTIC ACID; TRAMADOL; TRANDOLAPRIL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; DIABETIC NEUROPATHY; DIABETIC SENSORIMOTOR POLYNEUROPATHY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PAINFUL DIABETIC NEUROPATHY; PANCREAS TRANSPLANTATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84919629929     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622314552071     Document Type: Review

References (124)

1. Abbott C. Malik R. van Ross E. Kulkarni J. Boulton A. (2011) Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34: 2220–2224.
2. Agudo R. Valls-Sole J. Recasens M. Fabregat N. Ricart M. Esmatjes E. (2002) Effects of kidney and pancreas transplantation on neurophysiological rates of polyneuropathy and autonomous cardiac function in diabetic patients with end-stage renal disease. Med Clin (Barc) 118: 534–538.
3. Albers J. Herman W. Pop-Busui R. Feldman E. Martin C. Cleary P. et al. (2010) Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33: 1090–1096.
4. Arezzo J.C. Rosenstock J. Lamoreaux L. Pauer L. (2008) Efficacy and safety of pregabalin 600 mg / d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 8: 33.
5. Attal N. Cruccu G. Baron R. Haanpaa M. Hansson P. Jensen T. et al. (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17: 1113–1e88
6. Backonja M. Attal N. Baron R. Bouhassira D. Drangholt M. Dyck P. et al. (2013) Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG Consensus. Pain 154: 1807–1819.
7. Backonja M. Beydoun A. Edwards K. Schwartz S. Fonseca V. Hes M. et al. (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280: 1831–1836.
8. Bakkers M. Faber C. Hoeijmakers J. Lauria G. Merkies I. (2014) Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve 49: 329–336.
9. Bansal D. Bhansali A. Hota D. Chakrabarti A. Dutta P. (2009) Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 26: 1019–1026.
10. Barbano R. Herrmann D. Hart-Gouleau S. Pennella-Vaughan J. Lodewick P. Dworkin R. (2004) Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 61: 914–918.
11. Beard S. McCrink L. Le T. Garcia-Cebrian A. Monz B. Malik R. (2008) Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 24: 385–399.
12. Beydoun A. Shaibani A. Hopwood M. Wan Y. (2006) Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand 113: 395–404.
13. Boucek P. Havrdova T. Voska L. Lodererova A. He L. Saudek F. et al. (2008) Epidermal innervation in type 1 diabetic patients: a 2.5-year prospective study after simultaneous pancreas / kidney transplantation. Diabetes Care 31: 1611–1612.
14. Boulton A. Kempler P. Ametov A. Ziegler D. (2013) Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 29: 327–333.
15. Boussageon R. Bejan-Angoulvant T. Saadatian-Elahi M. Lafont S. Bergeonneau C. Kassai B. et al. (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343: d4169.
16. Brederson J. Kym P. Szallasi A. (2013) Targeting TRP channels for pain relief. Eur J Pharmacol 716: 61–76.
17. Brennan M.J. (2013) The effect of opioid therapy on endocrine function. Am J Med 126: S12–S18.
18. Bril V. (2012) Treatments for diabetic neuropathy. J Peripher Nerv Syst 17(Suppl. 2): 22–27.
19. Bril V. England J. Franklin G. Backonja M. Cohen J. Del Toro D. et al. (2011) Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 76: 1758–1765.
20. Callaghan B. Cheng H. Stables C. Smith A. Feldman E. (2012 a) Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 11: 521–534.
21. Callaghan B. Feldman E. Liu J. Kerber K. Pop-Busui R. Moffet H. et al. (2011) Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care 34: 635–640.
22. Callaghan B. Little A. Feldman E. Hughes R. (2012 b) Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 6: CD007543.
23. Campbell C. Kipnes M. Stouch B. Brady K. Kelly M. Schmidt W. et al. (2012) Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 153: 1815–1823.
24. Cella D. Lai J. Nowinski C. Victorson D. Peterman A. Miller D. et al. (2012) Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 78: 1860–1867.
25. Chen W. Yang G. Liu B. Manheimer E. Liu J. (2013) Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PloS ONE 8: e73764.
26. Chong M. Hester J. (2007) Diabetic painful neuropathy: current and future treatment options. Drugs 67: 569–585.
27. Christoph T. Schroder W. Tallarida R. de Vry J. Tzschentke T. (2013) Spinal-supraspinal and intrinsic mu-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 347: 794–801.
28. Cleeland C. Ryan K. (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129–138.
29. Cohen K. Harris S. (1987) Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 147: 1442–1444.
30. Cotter M. Ekberg K. Wahren J. Cameron N. (2003) Effects of proinsulin c-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52: 1812–1817.
31. Daousi C. Macfarlane I. Woodward A. Nurmikko T. Bundred P. Benbow S. (2004) Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 21: 976–982.
32. Del Carro U. Fiorina P. Amadio S. de Toni Franceschini L. Petrelli A. Menini S. et al. (2007) Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 30: 3063–3069.
33. Derry S. Lloyd R. Moore R. McQuay H. (2009) Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev: CD007393.
34. Dogra S. Beydoun S. Mazzola J. Hopwood M. Wan Y. (2005) Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 9: 543–554.
35. Donofrio P. Raskin P. Rosenthal N. Hewitt D. Jordan D. Xiang J. et al. (2005) Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther 27: 1420–1431.
36. Dworkin R. O'Connor A. Audette J. Baron R. Gourlay G. Haanpaa M. et al. (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(Suppl.3): S3–S14.
37. Dyck P. Norell J. Tritschler H. Schuette K. Samigullin R. Ziegler D. et al. (2007) Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 30: 2619–2625.
38. Eisenberg E. Lurie Y. Braker C. Daoud D. Ishay A. (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57: 505–509.
39. Feldman E. Stevens M. Thomas P. Brown M. Canal N. Greene D. (1994) A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17: 1281–1289.
40. Fioretto P. Steffes M. Sutherland D. Goetz F. Mauer M. (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69–75.
41. Fried L. Forrest K. Ellis D. Chang Y. Silvers N. Orchard T. (2001) Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 15: 113–119.
42. Galer B. Gianas A. Jensen M. (2000) Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 47: 123–128.
43. Galloway C. Chattopadhyay M. (2013) Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in type 2 diabetes. Cytokine 63: 1–5.
44. Garrow A. Xing M. Vere J. Verrall B. Wang L. Jude E. (2014) Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT. Acupunct Med 32: 242–249.
45. Gilron I. Bailey J. Tu D. Holden R. Jackson A. Houlden R. (2009) Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 374: 1252–1261.
46. Gilron I. Bailey J. Tu D. Holden R. Weaver D. Houlden R.L. (2005) Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352: 1324–1334.
47. Gimbel J. Richards P. Portenoy R. (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60: 927–934.
48. Goldberg Y. Price N. Namdari R. Cohen C. Lamers M. Winters C. et al. (2012) Treatment of Na(V)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain 153: 80–85.
49. Goldstein D. Lu Y. Detke M. Lee T. Iyengar S. (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116: 109–118.
50. Goto Y. Hotta N. Shigeta Y. Sakamoto N. Kikkawa R. (1995) Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 49: 269–277.
51. Grosskopf J. Mazzola J. Wan Y. Hopwood M. (2006) A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 114: 177–180.
52. Hammes H. Du X. Edelstein D. Taguchi T. Matsumura T. Ju Q. et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9: 294–299.
53. Harati Y. Gooch C. Swenson M. Edelman S. Greene D. Raskin P. et al. (1998) Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50: 1842–1846.
54. Herman W. Aubert R. Engelgau M. Thompson T. Ali M. Sous E. et al. (1998) Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med 15: 1045–1051.
55. Hollingshead J. Duhmke R. Cornblath D. (2006) Tramadol for neuropathic pain. Cochrane Database Syst Rev: CD003726.
56. Hotta N. Akanuma Y. Kawamori R. Matsuoka K. Oka Y. Shichiri M. et al. (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29: 1538–1544.
57. Kamiya H. Zhang W. Sima A. (2004) C-Peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 56: 827–835.
58. Kelly K. Cook T. Backonja M. (2005) Pain ratings at the thresholds are necessary for interpretation of quantitative sensory testing. Muscle Nerve 32: 179–184.
59. Kennedy W. Navarro X. Goetz F. Sutherland D. Najarian J. (1990) Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 322: 1031–1037.
60. Klimis H. Adams D. Callaghan B. Nevin S. Alewood P. Vaughan C. et al. (2011)A novel mechanism of inhibition of high-voltage activated calcium channels by alpha-conotoxins contributes to relief of nerve injury-induced neuropathic pain. Pain 152: 259–266.
61. Krause S. Backonja M. (2003) Development of a neuropathic pain questionnaire. Clin J Pain 19: 306–314.
62. Kvinesdal B. Molin J. Froland A. Gram L. (1984) Imipramine treatment of painful diabetic neuropathy. JAMA 251: 1727–1730.
63. Leiter L. (2005) The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 68(Suppl. 2): S3–S14.
64. Lesser H. Sharma U. Lamoreaux L. Poole R. (2004) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63: 2104–2110.
65. Lunn M. Hughes R. Wiffen P. (2009) Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev: CD007115.
66. Lunn M. Hughes R. Wiffen P. (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev (1): CD007115.
67. Mahoney J. Vardaxis V. Moore J. Hall A. Haffner K. Peterson M. (2012) Topical ketamine cream in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc 102: 178–183.
68. Malik R. Tesfaye S. Ziegler D. (2013) Medical strategies to reduce amputation in patients with type 2 diabetes. Diabet Med 30: 893–900.
69. Malik R. Williamson S. Abbott C. Carrington A. Iqbal J. Schady W. et al. (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352: 1978–1981.
70. Max M. Kishore-Kumar R. Schafer S. Meister B. Gracely R. Smoller B. et al. (1991) Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 45: 3–9; discussion 1–2.
71. Max M. Lynch S. Muir J. Shoaf S. Smoller B. Dubner R. (1992) Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326: 1250–1256.
72. McGowan E. Hoyt S. Li X. Lyons K. Abbadie C. (2009) A peripherally acting Na(V)1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth Analg 109: 951–958.
73. Mehra S. Tavakoli M. Kallinikos P. Efron N. Boulton A. Augustine T. et al. (2007) Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 30: 2608–2612.
74. Mellegers M. Furlan A. Mailis A. (2001) Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain 17: 284–295.
75. Moore R. Straube S. Wiffen P. Derry S. McQuay H. (2009 a) Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev: CD007076.
76. Moore R. Wiffen P. Derry S. McQuay H. (2011) Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev: CD007938.
77. Moore T. Jones T. Browder J. Daffron S. Passik S. (2009 b) A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med 10: 1426–1433.
78. National Institute for Health and Clinical Excellence (2013) Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings. Clinical Guidance 173. London: National Institute for Health and Care Excellence.
79. Navarro X. Sutherland D. Kennedy W. (1997) Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 42: 727–736.
80. Oates P.J. (2002) Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 50: 325–392.
81. Oyibo S. Prasad Y. Jackson N. Jude E. Boulton A. (2002) The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 19: 870–873.
82. Papanas N. Ziegler D. (2011) New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications 25: 44–51.
83. Polydefkis M. Hauer P. Sheth S. Sirdofsky M. Griffin J. McArthur J. (2004) The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 127: 1606–1615.
84. Rajamani K. Colman P. Li L. Best J. Voysey M. D'Emden M. et al. (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373: 1780–1788.
85. Raskin P. Donofrio P. Rosenthal N. Hewitt D. Jordan D. Xiang J. et al. (2004) Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63: 865–873.
86. Rice A. Dworkin R. McCarthy T. Anand P. Bountra C. McCloud P. et al. (2014) EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383: 1637–1647.
87. Richter R. Portenoy R. Sharma U. Lamoreaux L. Bockbrader H. Knapp L. (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6: 253–260.
88. Rosenstock J. Tuchman M. Lamoreaux L. Sharma U. (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110: 628–638.
89. Rowbotham M. Goli V. Kunz N. Lei D. (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110: 697–706.
90. Rudroju N. Bansal D. Talakokkula S. Gudala K. Hota D. Bhansali A. et al. (2013) Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician 16: E705–E714.
91. Rull J. Quibrera R. Gonzalez-Millan H. Lozano Castaneda O. (1969) Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 5: 215–218.
92. Saarto T. Wiffen P. (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev: CD005454.
93. Sanford M. (2013) Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. CNS Drugs 27: 989–1002.
94. Sang C. Booher S. Gilron I. Parada S. Max M. (2002) Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose–response trials. Anesthesiology 96: 1053–1061.
95. Schwartz S. Etropolski M. Shapiro D. Okamoto A. Lange R. Haeussler J. et al. (2011) Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 27: 151–162.
96. Shaibani A. Pope L. Thisted R. Hepner A. (2012) Efficacy and safety of dextromethorphan / quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med 13: 243–254.
97. Shy M. Frohman E. So Y. Arezzo J. Cornblath D. Giuliani M. et al. (2003) Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 60: 898–904.
98. Sicras A. Rejas J. Navarro R. Planas A. (2013) Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis. Clin Drug Investig 33: 825–835.
99. Sindrup S. Ejlertsen B. Froland A. Sindrup E. Brosen K. Gram L. (1989) Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 37: 151–153.
100. Sindrup S. Gram L. Skjold T. Froland A. Beck-Nielsen H. (1990) Concentration–response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 47: 509–515.
101. Smith A. Russell J. Feldman E. Goldstein J. Peltier A. Smith S. et al. (2006) Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 29: 1294–1299.
102. Smith M. Wyse B. Edwards S. (2013) Small molecule angiotensin II type 2 receptor (AT (2)R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med 14: 692–705.
103. Sorensen L. Molyneaux L. Yue D. (2002) Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 57: 45–51.
104. Spallone V. (2012) Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep 12: 403–413.
105. Stracke H. Gaus W. Achenbach U. Federlin K. Bretzel R. (2008) Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 116: 600–605.
106. Tavakoli M. Mojaddidi M. Fadavi H. Malik R. (2008) Pathophysiology and treatment of painful diabetic neuropathy. Curr Pain Headache Rep 12: 192–197.
107. Tesfaye S. Stevens L. Stephenson J. Fuller J. Plater M. Ionescu-Tirgoviste C. et al. (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 39: 1377–1384.
108. Tesfaye S. Wilhelm S. Lledo A. Schacht A. Tolle T. Bouhassira D. et al. (2013) Duloxetine and pregabalin: high-dose monotherapy or their combination? The ‘COMBO-DN Study’ – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 154: 2616–2625.
109. Thakral G. Kim P. Lafontaine J. Menzies R. Najafi B. Lavery L. (2013) Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy. J Diabetes Sci Technol 7: 1202–1209.
110. The Capsaicin Study Group (1991) Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 151: 2225–2229.
111. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.
112. Thienel U. Neto W. Schwabe S. Vijapurkar U. and Topiramate Diabetic Neuropathic Pain Study Group (2004) Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 110: 221–231.
113. Thisted R. Klaff L. Schwartz S. Wymer J. Culligan N. Gerard G. et al. (2006) Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: A 29-day, multicenter, open-label, dose-escalation study. Clin Ther 28: 1607–1618.
114. Verheyen A. Peeraer E. Lambrechts D. Poesen K. Carmeliet P. Shibuya M. et al. (2013) Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. Neuroscience 244: 77–89.
115. Vincent A. Callaghan B. Smith A. Feldman E. (2011) Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 7: 573–583.
116. Watson C. Moulin D. Watt-Watson J. Gordon A. Eisenhoffer J. (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105: 71–78.
117. Weintrob N. Amitay I. Lilos P. Shalitin S. Lazar L. Josefsberg Z. (2007) Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complications 21: 13–19.
118. Wiffen P. Derry S. Moore R. (2013) Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev (12): CD006044.
119. Wiggin T. Sullivan K. Pop-Busui R. Amato A. Sima A. Feldman E. (2009) Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58: 1634–1640.
120. Wilton T. (1974) Tegretol in the treatment of diabetic neuropathy. S Afr Med J 48: 869–872.
121. Yuan R. Sheu J. Yu J. Chen W. Tseng I. Chang H. et al. (2009) Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72: 1473–1478.
122. Zhang W. Li Wan Po A. (1994) The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 46: 517–522.
123. Ziegler D. Nowak H. Kempler P. Vargha P. Low P. (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21: 114–121.
124. Ziegler D. Rathmann W. Dickhaus T. Meisinger C. Mielck A. and KORA Study Group (2009) Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA / KORA Augsburg Surveys S2 and S3. Pain Med 10: 393–400.